tbuckley/cabot-search huggingface dataset:
Patient organisations failed to disclose £14m in drug company payments over four years, study finds
Authors: Elisabeth Mahase
Journal: BMJ (2020)

Patient organisations failed to declare over £14m (€15.3m; $18m) in payments from pharmaceutical companies between 2012 and 2016, according to a study from BMJ Open .1

The paper compared drug company (87) and patient organisation (425) disclosure reports in the UK and found that there were 1472 payments equalling £14 023 475 missing from the reports from 225 patient groups. Meanwhile, there were 128 payments missing from drug company records, equating to £1.6m.

Researchers have declared that the current systems to track payments that drug companies make and patient organisations receive are not working and called for a single, state run, permanent database integrating payments reported by drug companies and patient organisations in order …
LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer
Authors: P.A. Konstantinopoulos, A.A. Gockley, N. Xiong, N. Tayob, C.N. Krasner, M. Buss, S. Campos, S. Schumer, A.A. Wright, J.F. Liu, M. Shea, Y. Oladapo, C. Castro, M.M. Polak, C. Whalen, S. Bouberhan, S.A. Cannistra, R.T. Penson, G. Fleming, U.A. Matulonis
Journal: Annals of Oncology (2020)
1699P COVID-19 pandemic: Patients’ perspective during cancer treatment
Authors: F. Merloni, N. Ranallo, L. Bastianelli, F. Vitarelli, L. Cantini, Z. Ballatore, G. Ricci, I. Fiordoliva, L. Tassone, B. Ferretti, P. Alessandroni, M. Del Prete, S. Chiorrini, M. Safi, L. Stocchi, G. Benedetti, L. Faloppi, R. Stoico, R. Berardi
Journal: Annals of Oncology (2020)
1178P Impact of comprehensive genomics profiling on treatment management of patients with advanced neuroendocrine neoplasms
Authors: A. Garcia-Alvarez, J. Hernando, A. Vivancos, S. Landolfi, A. Casteras, M. Simo, A. Garcia Burillo, L. Blanco, L. Trejo, M. Diez Garcia, D.A. Acosta Eyzaguirre, J. Capdevila
Journal: Annals of Oncology (2020)
1969P The SGLT2 inhibitor dapagliflozin enhanced anticancer activities and exerts cardioprotective effects against doxorubicin and trastuzumab toxicity through TLR4, MyD88, NF-kB signaling and NLRP3 inflammasome pathway
Authors: N. Maurea, V. Quagliariello, A. Bonelli, A. Caronna, I. Grimaldi, C. Lombari, G. Conforti, G. Botti
Journal: Annals of Oncology (2020)
Urgent Need for Studies of the Late Effects of SARS-CoV-2 on the Cardiovascular System
Authors: Joseph J. Maleszewski, Phillip M. Young, Michael J. Ackerman, Marc K. Halushka
Journal: Circulation (2020)

COVID-19 are not associated with true myocarditis in most cases and suggest a more frequent secondary and perhaps transient heart involvement.More autopsy studies, both acute and delayed relative to infection, will contextualize our understanding of the pathobiology of SARS-CoV-2.A diverse set of cardiovascular effects of COVID-19 will likely be seen, and it is essential to calculate each population's risk and understand their time courses.It would be unwise to have the tail wag the dog on policy decisions or predictions of long-term needs of the health care system where extremely rare outcomes guide the overall approach to the disease.We must properly gauge the frequency of late cardiovascular events from much larger and robust data sources.Ultimately, there is a need to balance the long-term societal COVID-19 health risks with other considerations of individual physical, mental, and emotional health.
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
Authors: Jordan Gauthier, Evandro D. Bezerra, Alexandre V. Hirayama, Salvatore Fiorenza, Alyssa Sheih, Cassie K. Chou, Erik L. Kimble, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Tinh-Doan Phi, Rachel N. Steinmetz, Abby W. Jamieson, Merav Bar, Ryan D. Cassaday, Aude G. Chapuis, Andrew J. Cowan, Damian J. Green, Hans-Peter Kiem, Filippo Milano, Mazyar Shadman, Brian G. Till, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle
Journal: Blood (2020)
Small diameter shunts should lead to safe expansion of the use of TIPS
Authors: Jaume Bosch
Journal: Journal of Hepatology (2020)

Transjugular intrahepatic portosystemic shunt (TIPS) is increasingly used worldwide to treat the complications of portal hypertension in patients with advanced cirrhosis. However, its use is hampered by the risk of causing hepatic encephalopathy and of worsening liver function. The reported haemodynamic targets used to guide TIPS are too narrow to be achieved in most cases and are perhaps not entirely adequate nowadays as they were obtained in the pre-covered stent era. We propose that small diameter TIPS - alone or combined to pharmacological therapy or ancillary interventional radiology procedures - may overcome these limitations while maintaining the beneficial effects of the procedure.
LBA10 Critical role of eosinophils during response to immune checkpoint blockade in breast cancer and other cancer types
Authors: L. Voorwerk, H. Garner, O.S. Blomberg, L. Spagnuolo, M. Chalabi, E. van Dyk, O.I. Isaeva, N. Bakker, C. Klaver, M. Duijst, K. Kersten, L.R. Hoes, J. van Dorp, M.S. van der Heijden, W.S.M.E. Theelen, E.E. Voest, L.F. Wessels, K.E. de Visser, M. Kok
Journal: Annals of Oncology (2020)
Accuracy of Physicians’ Electrocardiogram Interpretations
Authors: David A. Cook, So-Young Oh, Martin V. Pusic
Journal: JAMA Internal Medicine (2020)

The electrocardiogram (ECG) is the most common cardiovascular diagnostic test. Physicians' skill in ECG interpretation is incompletely understood.To identify and summarize published research on the accuracy of physicians' ECG interpretations.A search of PubMed/MEDLINE, Embase, Cochrane CENTRAL (Central Register of Controlled Trials), PsycINFO, CINAHL (Cumulative Index to Nursing and Allied Health), ERIC (Education Resources Information Center), and Web of Science was conducted for articles published from database inception to February 21, 2020.Of 1138 articles initially identified, 78 studies that assessed the accuracy of physicians' or medical students' ECG interpretations in a test setting were selected.Data on study purpose, participants, assessment features, and outcomes were abstracted, and methodological quality was appraised with the Medical Education Research Study Quality Instrument. Results were pooled using random-effects meta-analysis.Accuracy of ECG interpretation.Of 1138 studies initially identified, 78 assessed the accuracy of ECG interpretation. Across all training levels, the median accuracy was 54% (interquartile range [IQR], 40%-66%; n = 62 studies) on pretraining assessments and 67% (IQR, 55%-77%; n = 47 studies) on posttraining assessments. Accuracy varied widely across studies. The pooled accuracy for pretraining assessments was 42.0% (95% CI, 34.3%-49.6%; n = 24 studies; I2 = 99%) for medical students, 55.8% (95% CI, 48.1%-63.6%; n = 37 studies; I2 = 96%) for residents, 68.5% (95% CI, 57.6%-79.5%; n = 10 studies; I2 = 86%) for practicing physicians, and 74.9% (95% CI, 63.2%-86.7%; n = 8 studies; I2 = 22%) for cardiologists.Physicians at all training levels had deficiencies in ECG interpretation, even after educational interventions. Improved education across the practice continuum appears warranted. Wide variation in outcomes could reflect real differences in training or skill or differences in assessment design.
1336P Patients with EGFR exon 20 insertion mutation non-small cell lung cancer benefit from pemetrexed-based chemotherapy: A multicenter study
Authors: W. Wang, C. Xu, L. Lei, D. Wang, X. Pu, Y. Zhu, J. Huang, Z. Yu, J. Li, Y. Fang, H. Wang, W. Zhuang, S. Lan, X. Cai, Y. Zhang, W. Gao, L. Wang, M. Fang, T. Lv, Y. Song
Journal: Annals of Oncology (2020)
1800P Concordance between treatment-naive tissue and circulating tumour DNA (ctDNA) in late stage non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
Authors: C. Woestmann, J. Jiang, J.F. Palma, C. Ju, C.P. Heussel, M. Kriegsmann, S. Yaung, M. Thomas, M. Meister, M. Schneider, F. Herth, T. Muley, B. Wehnl, B. Hinzmann
Journal: Annals of Oncology (2020)
1377P Exploratory analyses of efficacy from a phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC
Authors: D. Planchard, D. Shin, J. Choi, Y. Seo, J.A. Jung, M. Park, M. Reck
Journal: Annals of Oncology (2020)
255P Predictive factors of distant recurrence disease in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy
Authors: J. Ponce, A. Rodriguez-Lescure, S. Delgado, G. Peiró, M. Pastor-Valero, M. Reche, I. Lozano, B. Massuti Sureda
Journal: Annals of Oncology (2020)
665P Impact of enzalutamide on patient-reported fatigue in hormone-sensitive prostate cancer (HSPC) or castration-resistant prostate cancer (CRPC)
Authors: B.F. Tombal, S.J. Freedland, A.J. Armstrong, T.M. Beer, A. Stenzl, C.N. Sternberg, M. Hussain, A. Ganguli, K. Ramaswamy, H.S. Bhadauria, C. Ivanescu, J. Turnbull, S. Holmstrom, F. Saad
Journal: Annals of Oncology (2020)
325P Characteristics of patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer who achieved durable response in the phase III BROCADE3 study
Authors: B. Kaufman, H. Han, B. Arun, H. Wildiers, M. Friedlander, J-P. Ayoub, S. Puhalla, D. Maag, D. Feng, S. Fages, V.C. Dieras
Journal: Annals of Oncology (2020)
799TiP PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations
Authors: D.M. Somford, S. Daneshmand, P. Grivas, S. Sridhar, S. Gupta, J. Bellmunt, G. Sonpavde, M.T. Fleming, S.P. Lerner, Y. Loriot, A. Li, H. Takkele, C. Andresen, J. Rearden, S. Peacock Shepherd, M.J. Schnabel, S.K. Pal
Journal: Annals of Oncology (2020)
168MO GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status
Authors: T. Link, J-U. Blohmer, M. Just, M. Untch, O. Stötzer, P.A. Fasching, A. Schneeweiss, P. Wimberger, S. Seiler, J. Huober, W.D. Schmitt, C. Jackisch, K.E. Rhiem, C. Hanusch, C. Denkert, B.V. Sinn, K. Engels, V. Nekljudova, S. Loibl
Journal: Annals of Oncology (2020)
1703P UK Coronavirus Cancer Monitoring Project (UKCCMP): A national reporting network for real time data of the COVID-19 pandemic
Authors: A.C. Olsson-Brown, D.J. Hughes, K. Purshouse, L. Lee, V.W. Cheng, A.J.X. Lee, E. Protheroe, A. Smith, H. Curley, R. Arnold, J-B. Cazier, J. D'Costa, C. Palles, N. Campton, C. Varnai, S. Sivakumar, R. Kerr, G. Middleton
Journal: Annals of Oncology (2020)
1866P Preliminary quality of life and safety results of naloxegol for patients with cancer pain diagnosed with opioid induced constipation. NACASY study
Authors: D. Dupoiron, V. Montesarchio, J. Lecrerc, S. Cinieri, S. España, A. Fernandez, J.L. Sanz, J. Tack, A. Davies
Journal: Annals of Oncology (2020)
599TiP BT8009-100 phase I/II study of the safety, pharmacokinetics, &amp; preliminary clinical activity of BT8009 in patients with Nectin-4 expressing advanced malignancies
Authors: M. Mckean, J.C. Bendell, D.P. Petrylak, T.B. Powles, G.P. Sonpavde, A. Dickson, L. Dosunmu, M.G. Hennessy, P. Jeffrey, M. Rigby, T. West
Journal: Annals of Oncology (2020)
Primary Inferior Vena Cava Leiomyosarcoma With Hepatic Metastases on FDG PET/CT
Authors: Sijuan Zou, Jianyuan Zhou, Ming Tang, Ziqing Wang, Xiaohua Zhu
Journal: Clinical Nuclear Medicine (2020)

Leiomyosarcomas originating from the inferior vena cava are very rare malignant tumors with an extremely poor prognosis. We report FDG PET/CT findings of pathology-proven hepatic metastases from leiomyosarcoma originating from the inferior vena cava in a young woman whose initial presentation was worsening abdominal and chest pain.
State-level prescription drug monitoring program mandates and adolescent injection drug use in the United States, 1995–2017: A difference-in-differences analysis
Authors: Joel J. Earlywine, Scott E. Hadland, Julia Raifman
Journal: PLoS Medicine (2020)

Background Prescription opioid misuse is an ongoing crisis and a risk factor for injection drug use (IDU). Few studies have evaluated strategies for preventing opioid or IDU initiation among adolescents. We evaluated changes in the proportion of adolescents reporting IDU before and after prescription drug monitoring program (PDMP) mandates were implemented in 18 states compared to 29 states without such mandates. Methods and findings This difference-in-differences analysis used biannual Youth Risk Behavioral Surveillance System (YRBSS) data representative of adolescents 17 to 18 years old across 47 states from 1995 to 2017. We compared changes in adolescent IDU in 18 states with and 29 states without PDMP mandates. Among 331,025 adolescents, 51.7% identified as male, 62.1% as non-Hispanic white, 17.4% as non-Hispanic black, and 14.6% as Hispanic. Overall, 3.5% reported IDU during the 2 years prior to PDMP mandates. In the final multivariable difference-in-differences model, we included individual age, sex, and race/ethnicity, as well as state and year as covariates from the YRBSS. We also included state- and year-specific poverty rates based on US Census Bureau data. Additionally, we controlled for state implementation of (non-mandated) PDMPs before states subsequently implemented mandates and pill mill laws. We conducted several sensitivity analyses, including repeating our main analysis using a logistic, rather than linear, model, and with a lead indicator on PDMP mandate implementation, a lag indicator, and alternative policy implementation dates. PDMP mandates were associated with a 1.5 percentage point reduction (95% CI −2.3 to −0.6 percentage points; p = 0.001) in adolescent IDU, on average over the years following mandate implementation, a relative reduction of 42.9% (95% CI −65.7% to −17.1%). The association of PDMP mandates with this reduction persisted at least 4 years beyond implementation. Sensitivity analyses were consistent with the main results. Limitations include the multi-stepped causal pathway from PDMP mandate implementation to changes in IDU and the potential for omitted state-level time-varying confounders. Conclusions Our analysis indicated that PDMP mandates were associated with a reduction in adolescent IDU, providing empirical evidence that such mandates may prevent adolescents from initiating IDU. Policymakers might consider PDMP mandates as a potential strategy for preventing adolescent IDU.
1548P Favourable prognostic significance of membranous β-catenin expression and negative prognostic significance of cytoplasmic β-catenin expression in pancreatic cancer
Authors: J. Dvorak, B. Rosova, A. Filipova, D. Hadzi Nikolov, R. Chloupkova, J. Proks, I. Richter, P. Szabo, A. Rozsypalova, R. Matej, B. Melichar, T. Buchler
Journal: Annals of Oncology (2020)
Corneal endothelial dysfunction: Evolving understanding and treatment options
Authors: Marianne O. Price, Jodhbir S. Mehta, Ula V. Jurkunas, Francis W. Price
Journal: Progress in Retinal and Eye Research (2020)

The cornea is exquisitely designed to protect the eye while transmitting and focusing incoming light. Precise control of corneal hydration by the endothelial cell layer that lines the inner surface of the cornea is required for optimal transparency, and endothelial dysfunction or damage can result in corneal edema and visual impairment. Advances in corneal transplantation now allow selective replacement of dysfunctional corneal endothelium, providing rapid visual rehabilitation. A series of technique improvements have minimized complications and various adaptations allow use even in eyes with complicated anatomy. While selective endothelial keratoplasty sets a very high standard for safety and efficacy, a shortage of donor corneas in many parts of the world restricts access, prompting a search for alternatives. Clinical trials are underway to evaluate the potential for self-recovery after removal of dysfunctional central endothelium in patients with healthy peripheral endothelium. Various approaches to using cultured human corneal endothelial cells are also in clinical trials; these aim to multiply cells from a single donor cornea for use in potentially hundreds of patients. Pre-clinical studies are underway with induced pluripotent stem cells, endothelial stem cell regeneration, gene therapy, anti-sense oligonucleotides, and various biologic/pharmacologic approaches designed to treat, prevent, or retard corneal endothelial dysfunction. The availability of more therapeutic options will hopefully expand access around the world while also allowing treatment to be more precisely tailored to each individual patient.
114P PD-L1 prevalence and association with clinical outcomes among metastatic renal cell carcinoma patients treated with targeted therapies
Authors: F. Donskov, C.A. Pinto, R. Predoui, F. Kong, C. Fox, J. Georgsen, K. Skaarup, R. Perini, T. Steiniche
Journal: Annals of Oncology (2020)
820P Phase II study of pamiparib in Chinese patients (pts) with advanced ovarian cancer (aOC)
Authors: X. Wu, J. Zhu, J. Wang, Z. Lin, B. Kong, R. Yin, W. Sun, Q. Zhou, S. Zhang, D. Wang, H. Shi, Y. Gao, Y. Huang, G. Li, X. Wang, Y. Cheng, G. Lou, L. Li, X. Mu, M. Li
Journal: Annals of Oncology (2020)
1269P EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC)
Authors: B.Y. Shim, S. Lee, J. de Castro Carpeño, C-H. Chiu, M. Cobo, H.R. Kim, J.S. Ryu, M.M. Tarruella, Y. Summers, C.A. Thomas, Y. Xu, I. Lowy, P. Rietschel
Journal: Annals of Oncology (2020)
1399P Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)
Authors: J. Subramanian, V. Moreno, J. Bosch-Barrera, J. Pikiel, R. Kristeleit, W. Guo, H. Danaee, E. Im, D. Roda
Journal: Annals of Oncology (2020)
1539P Signature protein biomarkers in serum for diagnosis of pancreatic ductal adenocarcinoma
Authors: S.C. Lindgaard, E. Maag, I. Chen, A.Z. Johansen, C.P. Hansen, J.P. Hasselby, B.V. Jensen, S.E. Bojesen, K.R. Nielsen, D.L. Nielsen, J.S. Johansen
Journal: Annals of Oncology (2020)
PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma
Authors: Tian-Yi Jiang, Yu-Fei Pan, Zheng-Hua Wan, Yun-Kai Lin, Bin Zhu, Zhen-gang Yuan, Yun-Han Ma, Yuan-Yuan Shi, Tian-Mei Zeng, Li-Wei Dong, Ye-Xiong Tan, Hong-Yang Wang
Journal: Science Translational Medicine (2020)

Patient-derived xenografts (PDXs) and PDX-derived cells (PDCs) are useful in preclinical research. We performed a drug screening assay using PDCs and identified proteasome inhibitors as promising drugs for cholangiocarcinoma (CCA) treatment. Furthermore, we determined that phosphate and tensin homology deleted on chromosome ten (PTEN) deficiency promotes protein synthesis and proteasome subunit expression and proteolytic activity, creating a dependency on the proteasome for cancer cell growth and survival. Thus, targeting the proteasome machinery with the inhibitor bortezomib inhibited the proliferation and survival of CCA cells lacking functional PTEN. Therapeutic evaluation of PDXs, autochthonous mouse models, and patients confirmed this dependency on the proteasome. Mechanistically, we found that PTEN promoted the nuclear translocation of FOXO1, resulting in the increased expression of BACH1 and MAFF BACH1 and MAFF are transcriptional regulators that recognize the antioxidant response element, which is present in genes encoding proteasome subunits. PTEN induced the accumulation and nuclear translocation of these proteins, which directly repressed the transcription of genes encoding proteasome subunits. We revealed that the PTEN-proteasome axis is a potential target for therapy in PTEN-deficient CCA and other PTEN-deficient cancers.
Optimizing criteria for N-terminal pro-B-type natriuretic peptide for eligibility and enrichment in trials in heart failure with preserved, mid-range and reduced ejection fraction
Authors: G. Savarese, N. Orsini, C. Hage, Ola Vedin, F. Cosentino, G. Rosano, U. Dahlstrom, L. H. Lund
Journal: European Journal of Heart Failure (2018)
LBA47 Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial
Authors: B. Besse, M.R. Garcia Campelo, M.A. Cobo Dols, E. Quoix, A. Madroszyk, E. Felip, F. Cappuzzo, F. Denis, W. Hilgers, G. Romano, D. Debieuvre, E. Baldini, D. Galetta, S. Viteri, M. Phan, W. Schuette, A. Zer, D. Costantini, R. Dziadziuszko, G. Giaccone
Journal: Annals of Oncology (2021)
468P PANIB 20139173: Randomized, multicentre phase II trial comparing fluorouracil, leucovorin and oxaliplatin (FOLFOX) plus panitumumab versus FOLFOX plus bevacizumab in patients with previously untreated, RAS wild-type (WT) metastatic colorectal cancer (mCRC)
Authors: K. Janssens, E. Fransen, C.D. Rolfo, W. Lybaert, W. Demey, J. Decaestecker, K. Hendrickx, H. Kalantari, K. Op de Beeck, G. Van Camp, M. Peeters
Journal: Annals of Oncology (2020)
NSD3-Induced Methylation of H3K36 Activates NOTCH Signaling to Drive Breast Tumor Initiation and Metastatic Progression
Authors: Ga-Young Jeong, Mi Kyung Park, Hee-Joo Choi, Hee Woon An, Young-Un Park, Hyung-Jun Choi, Jin Park, Hyung-Yong Kim, Taekwon Son, Ho Lee, Kyueng-Whan Min, Young-Ha Oh, Jeong-Yeon Lee, Gu Kong
Journal: Cancer Research (2020)

Histone methyltransferase NSD3 is frequently dysregulated in human cancers, yet the epigenetic role of NSD3 during cancer development remains elusive. Here we report that NSD3-induced methylation of H3K36 is crucial for breast tumor initiation and metastasis. In patients with breast cancer, elevated expression of NSD3 was associated with recurrence, distant metastasis, and poor survival. In vivo, NSD3 promoted malignant transformation of mammary epithelial cells, a function comparable to that of HRAS. Furthermore, NSD3 expanded breast cancer-initiating cells and promoted epithelial-mesenchymal transition to trigger tumor invasion and metastasis. Mechanistically, the long isoform (full-length transcript) of NSD3, but not its shorter isoform lacking a catalytic domain, cooperated with EZH2 and RNA polymerase II to stimulate H3K36me2/3-dependent transactivation of genes associated with NOTCH receptor cleavage, leading to nuclear accumulation of NICD and NICD-mediated transcriptional repression of E-cadherin. Furthermore, mice harboring primary and metastatic breast tumors with overexpressed NSD3 showed sensitivity to NOTCH inhibition. Together, our findings uncover the critical epigenetic role of NSD3 in the modulation of NOTCH-dependent breast tumor progression, providing a rationale for targeting the NSD3-NOTCH signaling regulatory axis in aggressive breast cancer. SIGNIFICANCE: This study demonstrates the functional significance of histone methyltransferase NSD3 in epigenetic regulation of breast cancer stemness, EMT, and metastasis, suggesting NSD3 as an actionable therapeutic target in metastatic breast cancer.
392P Incidence, mortality and survival trends of central nervous system tumours in Cali, Colombia from 1962 to 2019: A population-based study
Authors: I. Riano, L.E. Bravo, P.A. Bravo-Valenzuela, L.S. Garcia, P. Collazos, E. Carrascal, T. Collazos
Journal: Annals of Oncology (2020)
1205P FACILITATE: A real-world multicentre prospective study investigating the utility of a rapid, fully automated RT-PCR assay vs reference methods (RM) for detecting epidermal growth factor receptor mutations (EGFRm) in NSCLC
Authors: M. Hummel, A. Behnke, A. Cayre, G. De Maglio, G. Giannini, L. Habran, B. Kah, E. Watkin
Journal: Annals of Oncology (2020)